
# **CDPG meeting** 27 May 2021








COVID-19 Situation in CARICOM


20 CARICOM Countries and CARICOM Associate Countries Antigua and Barbuda, Bahamas, Barbados, Belize, Dominica, Grenada, Guyana, Haiti, Jamaica, St Kitts and Nevis, St Lucia, St Vincent and the Grenadines, Suriname, Trinidad and Tobago, Anguilla, British Virgin Islands, Bermuda, Cayman Islands, Montserrat, Turks and Caicos	Cumulative cases <b>154.744</b>	Cumulative deaths <b>3011</b>	Cumulative recoverec <b>113.828</b>
29 CARICOM Countries and Associate Countries, and Dutch and French Territories Antigua and Barbuda, Bahamas, Barbados, Belize, Dominica, Grenada, Guyana, Haiti, Jamaica, St Kitts and Nevis, St Lucia, St Vincent and the Grenadines, Suriname, Trinidad and Tobago, Anguilla, British Virgin Islands, Bermuda, Cayman Islands, Montserrat, Turks and Caicos, Aruba, Curacao, St Maarten, Bonaire, St Eustatius, Saba, French Guiana, Guadeloupe, Martinique	Cumulative cases 233.395	Cumulative deaths <b>3747</b>	Cumulative recoverec 152.853

#### Cases % change last 14 days



### Decline in cases: 8 countries


Over 100% increase in 4 countries (St. Kittts and Nevis, Dominica, Cayman Islands, Haiti)






Decline in deaths: 5 countries 2-3 Increase: 3 countries (Trinidad and Tobago, Jamaica, Surinam, Barbados)

# COVID-19 Vaccine Access and Deployment in the Caribbean



	2nd WAVE					
	Quantity	Arrival				
Countries	Doses	Date	Supplier	Buyer	Status	
10	326,400	Apr/May	AstraZeneca AB	PAHO	Arrived	

## **Cumulative Doses administered**






Slidenss/MT No.

# **Retos de vacunación/Immunization challenges**

- Access to vaccines to cover the 80 % of population not currently covered by COVAX
- Funding for COVID-19 vaccines
- Vaccine hesitancy
- Falling coverage of routine vaccination
- Reduced surveillance of vaccine preventable diseases
  - Measles
  - Rubella
  - Polio







### Status of COVID-19 vaccines within WHO EUL/PQ 18 May 2021

	Manufacturer / WHO EUL holder	Name of Vaccine	NRA of Record	Platform	EOI accepted	Pre-submission meeting held	Dossier accepted for review*	Status of assessment**	Anticipated decision date***				
1.	Pfiner BONTECH	BNT162b2/COMIRNATY Tozinameran (INN)	EMA	Nucleoside modified mNRA	~	~	~	Finalized	31/12/20				
2.		AZD1222	EMA	Recombinant ChAdOx1 adenoviral vector encoding the			Accepted core data	Finalized	16 April 2021				
	AstaZeneca 2 Bosolec			Spike protein antigen of the SARS-CoV-2.	~	~	Data for Covax sites expected in April 2021 onwards	Finalized: SK-Catalent Wuxi (DS)	16 April 2021 30 April 2021				
з.		AZD1222	MFDS KOREA	Recombinant ChAdOx1				Other sites Finalized	As submitted 15 Feb 2021				
э.	AstraZerreca 🔁 🛃 estatuta	A201222	IMPDS KOREA	adenoviral vector encoding the Spike protein antigen of the SARS-CoV-2.	~	~	~	niaizeu	15 700 2021				
4.	CONTRACTOR OF THE PATILITY OF	Covishield (ChAdOx1_nCoV- 19)	DCGI	Recombinant ChAdOx1 adenoviral vector encoding the Spike protein antigen of the SARS-CoV-2.	~	~	~	Finalized	15 Feb 2021				
5.	Jansson T Infectious Diseases	Ad26.C0V2.5	EMA	Recombinant, replication- incompetent adenovirus type 26 (Ad26) vectored vaccine	~	~	Core data	Finalized (US +NL sites)	12 March 2021				
				encoding the (SARS-CoV-2) Spike (S) protein	1	encoding the (SARS-CoV-2) Spike	encoding the (SARS-CoV-2) Spike	encoding the (SARS-CoV-2) Spike			Additional sites: - Aspen South Africa - Other sites	- Ongoing - Awaited	- May 2021 - As submitted
6.	moderna	mRNA-1273	EMA	mNRA-based vaccine encapsulated in lipid nanoparticle (LNP)	~	~	~	Finalized	30 April 2021				
7.	🝸 Sinopharm / BIBP <sup>1</sup>	SARS-CoV-2 Vaccine (Vero Cell), inactivated (InCoV)	NMPA	Inactivated, produced in Vero cells	~	<b>~</b>	~	Finalized	07 May 2021				
8.	Sillovac	SARS-COV-2 Vaccine (Vero Cell), Inactivated	NMPA	Inactivated, produced in Vero cells	~	<b>~</b>	~	In progress	May 2021				
9.	THE GAMALEYA	Sputnik V	Russian NRA	Human Adenovirus Vector-based Covid-19 vaccine	Additional information submitted	Several meetings held.	"Rolling" submission of clinical and CMC data has started.	Additional data (Non-CLIN, CLIN, CMC) Required. Inspections in April, May and June 2021	Will be set after all data is submitted and inspections completed.				
10.	気 単 新 帯 诺 生 物 CanSinoBIO	Ad5-nCoV	NMPA	Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector)	~	~	Rolling data starting May 2021						
11.	NOVAVAX	NVX-CoV2373/Covovax	EMA	No pre-submission meeting yet.	Submitted EOI on 23 Feb	~							

### **Latest Publications and Technical Guidance**

#### Preventing and mitigating COVID-19 at work

The second

()) ==== (()) ===

chief features

Surveyses of MAR (etc.), by the Advector USAB (etc.) is not real to obtain a closely of sublicity and a protocol protocol and a sublicity of the sublicity o

To back the transmission of a second or shadow pairs is seen address pairs or proprior to constrain a pairs or a second or 1000 to the second pairs and the second pairs of the providence of the second pairs of the providence of the second pairs and the second pairs of the providence of the second pairs of the providence of the second pairs and the second pairs of the providence of the second pairs of

Where d is not prove according d priority interfaces constant of  $(dd^2+1)^{-1}$  , the subprise optimum is a presence of a solution of the priority of the solution of th

Table decision and events or product a table decision and the standards of the standards for the standard standards and the standards and the standards are standards and the standards and the standards are standards are standards are standards and the standards are standards are

The entropy of the analysis of the order of the order of the testing, VMC and Ref. we considered on the constraints of the analysis of the testing of the testing and the testing of testing of the testing of testing of the testing of testing

Notice the last particular term is a size of the mean start and a distance of the R  $_{\rm eff}$  and the mean start and the size of the R  $_{\rm eff}$  and the mean start and the size of the R  $_{\rm eff}$  and the mean start and the size of the size of

<u>Preventing and mitigating</u> <u>COVID-19 at work</u> 34<sup>th</sup> WHO Regulatory Update on COVID-19 <u>14 May 2021</u> World Hea Organizat

#### Key Messages

The COVID-19 pandemic has revealed the importance of data to support academics, researchers and industry in developing vaccines and therapeutics; to support regulators and health authorities in their decision-making; to support healthcare professionals in their treatment decisions; and to support public confidence in the vaccines and therapeutics being deployed. More than 50% of clinical trials are generally unreported by academics, researchers and industry, often because the results are negative. These unreported trial results have potential to hinder the design of best-suited trials, cause unnecessary testing and delay the development of innovative safe and efficacious treatments and vaccines. ICMRA and WHO call on the pharmaceutical industry to commit, within short timelines, and without waiting for legal changes, to provide voluntary access to trial results data for the benefit of public health, while personal data and individual patient data should be redacted.

#### Highlights and main issues

- B.1.617 is a variant has recently been designated as a WHO Variant of Concern. Preliminary evidence suggests potential reduced effectiveness of Barnlanivimab, a monoclonal antibody used for COVID-19 treatment, and potentially slightly reduced susceptibility to neutralization antibodies.
- A new WHO report provides a summary of global research initiatives and achievements to tackle COVID-19 agreed at the outset of the pandemic. The impact of regulation prices in acknowledged and mixing across for fiture regulated

<u>34<sup>th</sup> Regulatory</u> <u>update</u>

### COVID-19 natural immunity Scientific brief 10 May 2021

#### Key Messages:

- Within 4 weeks following infection, 90-99% of individuals infected with the SARS-CoV-2 virus develop detectable neutralizing antibodies.
- The strength and duration of the immune responses to SARS-CoV-2 are not completely understood and currently available data suggests that it varies by age and the severity of symptoms. Available scientific data suggests that in most people immune responses remain robust and protective against reinfoction for at least 6-8 months after infection (the longest follow up with storug scientific evidence iscurred approximately 8 months).
- Some variant SARS-CoV-2 viruses with key changes in the spike protein have a reduced susceptibility to neutralization by antibodies in the blood. While neutralizing antibodies mainly target the spike protein, cellular immunity clicified by natural infection also target other virual proteins, which then to be more conserved across variants than the spike protein. The ability of emerging virus variants (variants of interest and variants of concern) to evade immure responses is under investigation by researchers around the workl.
- There are many available serologic assays that measure the antibody response to SARS-CoV-2 infection, but at the present time, the correlates of protection are not well understood.

#### Objective of the scientific brief

### COVID-19 Natural immunity





# **Other updates and key messages**



Home / Newsroom / Feature stories / Detail / WHO advises that ivermectin only be used to treat COVID-19 with

### WHO advises that ivermectin only be used to treat COVID-19 within clinical trials

 PAHO. <u>Ongoing Living Update of Potential</u> <u>COVID-19 Therapeutics Options: Summary of</u> <u>Evidence. Rapid Review.</u>

 Ivermectin may not significantly reduce mortality and probably does not improve time to symptom resolution.  US administration will provide at least 80 million COVID-19 vaccines for Global use. The United States will work with COVAX and other partners to ensure these vaccines are delivered in a way that is equitable and follows the science and public health data. The United States will not use its vaccines to secure favors from other countries.





